CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.
CSA Medical wins CE Mark approval for RejuvenAir System
Published by Mass Device Medical Network CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB). The RejuvenAir system that is designed to apply...
Cryotherapy for COPD patients with Chronic Bronchitis approved in Europe
Published by RT Magazine Health officials in Europe OK’d CSA Medical’s cryotherapy system to treat chronic obstructive pulmonary disease (COPD) with chronic bronchitis. The system applies metered sprayed liquid nitrogen at -196 C to areas within the lungs through a...
CSA Medical Presents Positive Feasibility Study Results for its RejuvenAir® System at the 2019 European Respiratory Society International Congress
BOSTON, Oct. 3, 2019 /PRNewswire CSA Medical, Inc., presented positive 12-month results of its feasibility study for the RejuvenAir Metered Cryospray™ system yesterday at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain. In the...